Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Issue 7 (11th February 2015)

• Record Type: Journal Article
• Authors: Janssen, Julia M.; Heyward, William L.; Martin, J. Tyler; Janssen, Robert S.
• Is Part Of: Vaccine. Volume 33:Issue 7(2015)
• Page Start: 833
• Page End: 837
• Publication Date: 2015-02-11
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2014.12.060
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Phase 3 trial of investigational hepatitis B vaccine in CKD and diabetes.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">HBsAg-1018 induced superior seroprotection to HBsAg-Eng.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The safety profile of HBsAg-1018 was similar to that of HBsAg-Eng.</p> </list-item> </list> </p> </sec> </abstract>